Author Profile

Teva Cuts 250 Jobs at API Unit After Failing to Find a Buyer
The cuts will mostly affect the TAPI division in Israel and will roll out over the next two years. read more
GSK Buys Nuvalent for $10.6B in Lung Cancer Push
The Boston biotech has two oral kinase inhibitors already under FDA review. read more
Accelerating Value with Data
Big data and advanced technology have reshaped most industries, and oral solid dose is no exception. read more
BMS Secures Priority Review for Heart Drug in Adolescents
In a phase 3 trial, the drug met its primary endpoint and showed a safety profile consistent with that observed in adults. read more
Lilly's Oral GLP-1 Gets Phase 3 Win, Teeing Up Type 2 Diabetes Filing
Lilly shared phase 3 data for its once-daily GLP-1 tablet, Foundayo, across a broader set of patient populations than its approved obesity indication. read more
FDA Hits Cingulate with CRL for ADHD Tablet, Citing CMC Issues
The letter did not raise any concerns regarding the clinical safety or efficacy of CTx-1301. read more
Madrigal Oral MASH Drug Gets UK Approval
Rezdiffra is the first approved oral treatment for metabolic dysfunction-associated steatohepatitis in both the U.S. and UK. read more
Driving the Data-Rich Future of OSDs
Data-rich, data-led, data-driven — these terms increasingly define modern oral solid dose development. In this roundtable, industry leaders discuss what it will take to navigate this next phase of OSD innovation. read more
Servier Bets $2.65B on Edgewise Muscular Dystrophy Biz
The deal centers around Edgewise’s sevasemten, an investigative orally administered first-in-class fast skeletal myosin inhibitor. read more
BMS Oral CELMoD Candidate More Than Doubles Survival in Multiple Myeloma
Compared to the standard of care, the therapy led to a progression-free survival of 18 months vs. 8.3 months. read more
Shionogi Wins FDA Nod for First Oral Post-Exposure COVID Prevention
Between exposure and day 10, the drug reduced the risk of symptomatic COVID by 67%. read more
FDA Delays Decision on AstraZeneca Oral Breast Cancer Med
The agency is extending the PDUFA date for the company’s camizestrant combination, citing a need to review additional data to support the NDA. read more
Biogen, Denali Axe Parkinson’s Drug After Trial Fail
The LRRK2 inhibitor failed to slow the progression of idiopathic Parkinson’s disease and didn't meet any of the phase 2 trial’s secondary endpoints. read more
Phytolon Closes $23.6M Series B to Advance Beetroot Red Dye
The company offers a natural colorant portfolio, produced via fermentation of baker's yeast. read more
FDA Reshuffles Leadership After Makary Departure
Acting directors of CDER and CBER are both leaving their roles. read more
CapsCanada to Operate as Lyfe Group
The new identity is not the result of an acquisition or merger; it is a strategic step that consolidates the company's operations under one brand. read more
Amgen Partner Reports 20 Liver Injury-Related Deaths in Japan With Possible Link to Vasculitis Drug
Kissei Pharmaceutical has issued a safety alert regarding Tavneos. read more
BeOne Wins First FDA Nod for BCL2 Inhibitor in Mantle Cell Lymphoma
Beqalzi is the first approved BCL2 inhibitor to treat relapsed or refractory mantle cell lymphoma. read more
FDA Puts Hold on Aardvark Prader-Willi Syndrome Drug
Aardvark will be unblinding data from its phase 3 trials to find a way to continue the ARD-101 program. read more
AstraZeneca Wins FDA Nod for Oral Hypertension Drug
Baxfendy reduces systolic blood pressure by inhibiting the production of the hormone aldosterone, lowering the risk for heart and kidney problems. read more

May/June 2026

2026 Annual Buyer’s Guide
View Issue

Subscribe to Tablets & Capsules

Get started here for your complimentary print or digital subscription

Get started here for your complimentary print or digital subscription
Sign up Now »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox!